Ingredion Reports Record FY25 Results, Issues Cautious 2026 Outlook
summarizeSummary
Ingredion Inc. announced record full-year 2025 financial results, with adjusted EPS of $11.13, but reported a decline in Q4 2025 adjusted EPS and provided a cautious outlook for Q1 2026 and relatively flat full-year 2026 EPS guidance.
check_boxKey Events
-
Record Full-Year 2025 Performance
Reported and adjusted EPS reached $11.18 and $11.13, respectively, for full-year 2025, marking record financial results.
-
Mixed Q4 2025 Results
Fourth quarter adjusted EPS declined to $2.53 from $2.63 in Q4 2024, with adjusted operating income down 8%, primarily due to U.S./Canada operational issues.
-
2026 Full-Year Outlook
The company projects full-year 2026 reported and adjusted EPS in the range of $11.00 to $11.80, indicating a relatively flat to slightly positive growth trajectory.
-
Negative Q1 2026 Guidance
Ingredion anticipates Q1 2026 net sales to be down low single-digits and reported/adjusted operating income to be down mid-double digits.
auto_awesomeAnalysis
Ingredion Inc. delivered record full-year 2025 financial results, driven by strong performance in Texture & Healthful Solutions and LATAM. However, the fourth quarter saw a decline in adjusted EPS and operating income compared to the prior year, primarily due to operational challenges in the U.S./Canada segment and weaker sweetener demand. The company's full-year 2026 EPS outlook of $11.00 to $11.80 is largely flat compared to 2025 adjusted EPS, and the first quarter 2026 guidance anticipates a mid-double digit decline in operating income. This earnings report comes shortly after the announcement of CFO James Gray's retirement, who signed this filing. Investors will be watching for improvements in the U.S./Canada operations and the realization of the full-year guidance amidst a challenging Q1.
At the time of this filing, INGR was trading at $114.17 on NYSE in the Manufacturing sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $102.31 to $141.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.